greeksoup/ stock research
Stock research / United States / A · Laboratory Analytical Instruments · NYSE

Agilent Technologies, Inc. (A)

Agilent Technologies sells instruments, software, services and consumables covering the whole laboratory workflow, into life sciences, diagnostics and applied markets. It was incorporated in Delaware in May 1999. The financial year ends on 31 October. In November 2024 the company reorganised, and it now reports three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, with all historical segment figures recast to match. The former Diagnostics and Genomics segment was combined with the liquid chromatography platforms to make the first of those; chemistries and supplies, laboratory automation and software and informatics moved into CrossLab; and gas chromatography, remarketed instruments, spectroscopy and vacuum became Applied Markets.

Agilent Technologies, Inc.

Agilent Technologies sells instruments, software, services and consumables covering the whole laboratory workflow, into life sciences, diagnostics and applied markets. It was incorporated in Delaware in May 1999. The financial year ends on 31 October. In November 2024 the company reorganised, and it now reports three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, with all historical segment figures recast to match. The former Diagnostics and Genomics segment was combined with the liquid chromatography platforms to make the first of those; chemistries and supplies, laboratory automation and software and informatics moved into CrossLab; and gas chromatography, remarketed instruments, spectroscopy and vacuum became Applied Markets.

Life sciences and diagnostics

Seven areas of activity sit in this segment. It supplies active pharmaceutical ingredients for oligo-based therapeutics, and reagents, instruments, software and consumables that let customers in clinical and life sciences research examine samples at the cellular and molecular level. Liquid chromatography and liquid chromatography mass spectrometry are the instrument platforms here. Cell analysis covers instruments, reagents, software and labware for live-cell analysis platforms, plus flow cytometers, plate-readers and plate washers and dispensers. The segment also holds companion diagnostics, a contract development and manufacturing organisation providing specialty services for pharmaceutical customers, and biomolecular analysis. It sells mainly into pharmaceutical and biopharmaceutical, diagnostics and clinical, and academic and government markets, and also into chemicals and advanced materials, food and environmental, and forensics. There were approximately 22,200 customers in fiscal 2025.

Agilent CrossLab

CrossLab is the services and consumables business, spanning the whole lab rather than a single instrument. Services run to repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and custom work tailored to particular industries and to keeping instruments operational and compliant. Alongside that sit chemistries and supplies, software and informatics, and laboratory automation. There were approximately 59,700 CrossLab customers in fiscal 2025, many of whom also buy from the other two segments. The filing makes a point about how this segment behaves: services and consumables are mostly recurring and less exposed to market seasonality and industry cycles than the instrument businesses, and the vendor-neutral part of the portfolio performs relatively independently of Agilent's own instruments. The software business is tied to the installed base and to new instrument sales, and the automation business is the piece most tied to instrument cycles.

Applied Markets

This segment sells instruments and software that identify, quantify and analyse the physical and biological properties of substances and products. Gas chromatography and gas chromatography mass spectrometry cover testing for volatile and semi-volatile contaminants, so food safety, water and consumer product quality, fuels and chemical purity. The spectroscopy line, meaning inductively coupled plasma mass spectrometry, inductively coupled plasma optical emission spectrometry, atomic absorption and microwave plasma-atomic emission spectrometry, measures metals and elemental signatures in samples, used in food safety, environmental quality, chemicals manufacture, advanced materials and energy. Vacuum technology and remarketed instruments also sit here. There were approximately 17,200 customers in fiscal 2025, many of whom also buy from CrossLab.

How it sells and where it builds

Selling is multi-channel: direct sales to major accounts, supplemented by sales agents for broader geographic coverage and smaller accounts, a reseller programme, manufacturers' representatives and distributors, with consumables going through distributors, electronic commerce and direct sales. Manufacturing assembles highly configurable products to individual customer orders and makes standard products to stock, with third parties used selectively for some manufacturing, warehousing and logistics. United States plants sit in California, Colorado, Delaware, Iowa, Massachusetts, Texas and Vermont, and plants outside it in Canada, China, Denmark, Germany, Malaysia and Singapore. FDA registered sites are in California, Colorado, Texas, Vermont, Canada, Denmark and Germany.

The shared spine

Order fulfilment and supply chain operations are centralised in one organisation serving all three businesses, providing manufacturing, engineering and strategic sourcing. Behind that a global infrastructure organisation supplies shared finance, information technology, legal, some procurement, workplace services and human resources.

From Agilent Technologies' annual report on Form 10-K for the year ended 31 October 2025. The filing

Compare with another name What $10,000 in Agilent Technologies became

Next results: 23 Nov 2026, announced by the company (its release). Earnings calendar

Latest results

Latest quarterQ3 FY2026ended 31 July 2026 · 10-Q filed 1 September 2026
Revenue
$1.9 billion
+8.1% on the year · +2.3% on the quarter
Q4 FY2024Q3 FY2026
Net income
$362 million
+7.7% on the year · +6.8% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$1.28
+8.5% on the year · +6.7% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 October 2025 · 10-K filed 22 December 2025
Revenue
$6.9 billion
+6.7% on the year
FY2018FY2025
Net income
$1.3 billion
+1.1% on the year
FY2018FY2025
Diluted EPS
$4.57
+3.2% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsAgilent Technologies (A) reported revenue of $6.9 billion for fiscal 2025, the year ended 31 October 2025, up 6.7% on the year before. Net income was $1.3 billion and diluted earnings per share $4.57. Revenue was $6.5 billion in fiscal 2024, $6.8 billion in fiscal 2023, $6.8 billion in fiscal 2022 and $6.3 billion in fiscal 2021. Net income in the same years was $1.3 billion, $1.2 billion, $1.3 billion and $1.2 billion. Over the twelve months to 31 July 2026, Agilent Technologies reported revenue of $7.4 billion and net income of $1.4 billion. Revenue grew 5.4% a year, compounded, over the five years to fiscal 2025. Agilent Technologies declared $1.01 a share in dividends over the last four quarters and had 282 million shares outstanding at the latest filed count. At 31 July 2026 it carried $3.9 billion of debt and $1.8 billion of cash. At the close of 6 November 2026 the market cap of Agilent Technologies was $49.3 billion, 34.4 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE19.6%
ROCE14.5%
Operating margin22.2%
Net margin19.5%
FCF margin17.2%
Interest cover15.5x
Debt to equity0.54x
Cash conversion1.12x
Share count, last 12 months-0.6%
Sales CAGR, 3 years0.5%
Profit CAGR, 3 years1.3%
EPS, TTM$5.08

At the close of 6 November 2026

Price$174.75
Market cap$49.3 billion
Stock P/E34.4x
Price to book6.7x
EV / EBITDA26.9x
Dividend yield0.6%
Market cap / sales6.7x
52-week high$181.56
52-week low$110.24
Price, 1 year18.5%
Price CAGR, 3 years16.5%
Price CAGR, 5 years2.2%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Agilent Technologies, Inc.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.
Agreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue1,6601,6741,6071,7181,8491,7561,7171,6721,6881,6581,5731,5781,7011,6811,6681,7381,8611,7981,8351,878
Cost of revenue7607647467798377887931,014773750717723785782802850871852845836
Gross profit9009108619391,0129689246589159088568559168998668889909469901,042
Gross margin54%54%54%55%55%55%54%39%54%55%54%54%54%53%52%51%53%53%54%55%
R&D116117115116119123126118114128113127111113112111119117126123
SG&A389417386412422419415407393396380395397410454417428476465475
Operating income395376360411471426383133408384363333408376300360443353399444
Operating margin24%22%22%24%25%24%22%8%24%23%23%21%24%22%18%21%24%20%22%24%
Interest expense21.021.021.019.023.025.024.024.022.022.020.022.032.028.029.028.027.025.025.029.0
Pre-tax income448319333397455410377132420403374343401367260366442364408444
Tax rate1%11%18%17%19%14%20%16%-13%14%18%18%12%13%17%8%2%16%17%18%
Net income442283274329368352302111475348308282351318215336434305339362
Net margin27%17%17%19%20%20%18%7%28%21%20%18%21%19%13%19%23%17%18%19%
Diluted EPS$1.45$0.93$0.91$1.10$1.23$1.19$1.02$0.38$1.62$1.18$1.05$0.97$1.22$1.11$0.75$1.18$1.53$1.07$1.20$1.28
Operating cash flow441255283326448296398562516485333452481431221362545268277519
Capital expenditure62.075.064.082.070.076.057.081.084.090.010392.093.097.011410393.093.076.080.0
Free cash flow379180219244378220341481432395230360388334107259452175201439
Buybacks13644723432313575.085.033580.00.023058533590.016585.085.015265.078.0
Dividends paid59.063.063.062.062.067.066.066.066.069.069.068.068.071.070.071.070.072.072.072.0
Shares outstanding302m300m299m296m295m296m295m293m292m293m292m288m285m285m284m284m283m283m282m282m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008 †FY2009 †FY2010FY2011FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Revenue5,4205,7744,4815,4446,6156,8583,8944,0484,0384,2024,4724,9145,1635,3396,3196,8486,8336,5106,9487,372
Cost of revenue2,4512,5782,1892,5143,0863,2541,9872,0721,9972,0052,0632,2342,3582,5022,9123,1263,3682,9753,3053,404
Gross profit2,9693,1962,2922,9303,5293,6041,9071,9762,0412,1972,4092,6802,8052,8373,4073,7223,4653,5353,6433,968
Gross margin54.8%55.4%51.1%53.8%53.3%52.6%49.0%48.8%50.5%52.3%53.9%54.5%54.3%53.1%53.9%54.4%50.7%54.3%52.4%53.8%
Research and development685704642612649668337358330329341387404495441467481479455485
Selling, general and administrative1,7001,6971,6031,7521,8091,8171,1841,1991,1891,2531,2511,3891,4601,4961,6191,6371,6341,5681,7091,844
Operating income58479547.05661,0711,1193864195226158079049418461,3471,6181,3501,4881,4791,639
Operating margin10.8%13.8%1.0%10.4%16.2%16.3%9.9%10.4%12.9%14.6%18.0%18.4%18.2%15.8%21.3%23.6%19.8%22.9%21.3%22.2%
Interest expensen/a12388.096.086.010110711066.072.079.075.074.078.081.084.095.096.0112106
Pre-tax income6708153919381,3101,3847327637678599749469198421,3601,5041,3391,5211,4351,658
Income tax32.012238.08.020.0-11068.0-3.042.082.0119630-15212315025099.0232132218
Effective tax rate4.8%15.0%9.7%0.9%1.5%-7.9%9.3%-0.4%5.5%9.5%12.2%66.6%-16.5%14.6%11.0%16.6%7.4%15.3%9.2%13.1%
Net income638693-31.06841,0121,1537345494014626843161,0717191,2101,2541,2401,2891,3031,440
Net margin11.8%12.0%-0.7%12.6%15.3%16.8%18.8%13.6%9.9%11.0%15.3%6.4%20.7%13.5%19.1%18.3%18.1%19.8%18.8%19.5%
Diluted EPS$1.57$1.87-$0.09$1.94$2.85$3.27$2.13$1.62$1.20$1.40$2.10$0.97$3.37$2.30$3.94$4.18$4.19$4.43$4.57$5.08
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2009 to FY2025

FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Agilent CrossLab2,4182,7843,3163,3151,2241,3071,3301,4201,5311,7011,8401,1771,3601,4522,6562,7472,90841.9%
Life Sciences and Diagnostics Marketsn/an/an/an/an/an/an/an/an/an/an/an/an/an/a2,7802,4662,72639.2%
Applied Marketsn/an/an/an/an/an/an/an/an/an/an/an/an/an/a1,3971,2971,31418.9%
Diagnostics and Genomics8441,1961,5111,5596356636627908609431,0211,0471,2961,766n/an/an/an/a
Life Sciences1,2191,211n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Life Sciences and Applied Marketsn/an/a1,7881,9842,0352,0782,0461,9922,0812,2702,3023,1153,6633,630n/an/an/an/a
Agilent CrossLabLife Sciences and Diagnostics Markets FY2023 to FY2025Applied Markets FY2023 to FY2025Life Sciences and Applied Markets FY2011 to FY2022Diagnostics and Genomics FY2009 to FY2022Life Sciences FY2009 to FY2010
5,191FY20103,894FY20134,202FY20165,163FY20196,848FY20226,948FY2025

$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Profit by segment FY2013 to FY2025

The operating profit each segment reports. Costs Agilent Technologies does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.

FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Margin
FY2025
Agilent CrossLab29930129931633638847527232337083992594632.5%
Life Sciences and Diagnostics Marketsn/an/an/an/an/an/an/an/an/an/a67348453619.7%
Applied Marketsn/an/an/an/an/an/an/an/an/an/a36331230122.9%
Diagnostics and Genomics959388131167173185192273390n/an/an/an/a
Life Sciences and Applied Markets3383693804124705435427921,0171,097n/an/an/an/a
Agilent CrossLabLife Sciences and Diagnostics Markets FY2023 to FY2025Life Sciences and Applied Markets FY2013 to FY2022Applied Markets FY2023 to FY2025Diagnostics and Genomics FY2013 to FY2022
732FY2013767FY2015973FY20171,202FY20191,613FY20211,875FY20231,783FY2025

$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.

FY2025Share of salesShare of profit
Agilent CrossLab42%53%
Life Sciences and Diagnostics Markets39%30%
Applied Markets19%17%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.

Revenue by product or service FY2013 to FY2025

FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Non-Instrumentation and Othern/an/an/an/an/an/a3,0133,0903,6623,9414,0914,1564,52165.1%
Instrumentation1,8021,8391,8271,790n/an/a2,1502,2492,6572,9072,7422,3542,42734.9%
Analytical Lab Services768831843910n/an/an/an/an/an/an/an/an/an/a
Analytical lab consumables456476489510n/an/an/an/an/an/an/an/an/an/a
Diagnostics and genomics solutions635663662790n/an/an/an/an/an/an/an/an/an/a
Informatics and other233239217202n/an/an/an/an/an/an/an/an/an/a
Productsn/an/an/an/a3,3973,746n/an/an/an/an/an/an/an/a
Services and Othern/an/an/an/a1,0751,168n/an/an/an/an/an/an/an/a
Non-Instrumentation and Other FY2019 to FY2025Instrumentation FY2013 to FY2025Products FY2017 to FY2018Services and Other FY2017 to FY2018Analytical Lab Services FY2013 to FY2016Diagnostics and genomics solutions FY2013 to FY2016Analytical lab consumables FY2013 to FY2016Informatics and other FY2013 to FY2016
3,894FY20134,038FY20154,472FY20175,163FY20196,319FY20216,833FY20236,948FY2025

$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Revenue by region FY2012 to FY2025

FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Rest Of World2,8462,1982,4862,1312,1122,2582,4852,5252,5002,8872,9643,0403,0473,38248.7%
United States2,2181,0771,0191,2141,2511,3141,4141,6191,7522,1592,3852,4102,2462,34233.7%
China1,0786195436938399001,0151,0191,0871,2731,4991,3831,2171,22417.6%
Japan716n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Rest Of WorldUnited StatesChinaJapan FY2012
3,894FY20134,038FY20154,472FY20175,163FY20196,319FY20216,833FY20236,948FY2025

$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2007FY2008 †FY2009 †FY2010FY2011FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Operating cash flow9697564087181,2601,2281,1527315127938891,0871,0219211,4851,3121,7721,7511,5591,609
Capital expenditure15415412812118819419520598.0139176177155119188291298378407342
Free cash flow8156022805971,0721,0349575264146547139108668021,2971,0211,4741,3731,1521,267
Free cash flow margin15.0%10.4%6.2%11.0%16.2%15.1%24.6%13.0%10.3%15.6%15.9%18.5%16.8%15.0%20.5%14.9%21.6%21.1%16.6%17.2%
Cash from investing-456-399-14.0-1,1741,294-2,366-248-230-400-238-304-704-1,590-147-749-338-310-1,258-394-1,292
Cash from financing-980-774657601-1,693-37.0-554-117-1,089-268-202-797-299-717-696-1,372-930-752-715-95.0
Depreciation and amortisation191201162202253301372384253246212210238308321317271257288271
Share-based compensation13982.071.066.072.074.085.096.054.058.060.070.072.083.0110125111129128132
Buybacks1,9441,0011574114971729002002674341944227234697881,1395751,150425380
Dividends paidn/an/an/a0.00.0104156176133150170191206222236250265274282286
Dividend per sharen/an/an/a$0.00$0.00$0.30$0.46$0.53$0.40$0.46$0.53$0.60$0.66$0.72$0.78$0.84$0.90$0.94$0.99n/a
Diluted shares, weighted406m371m346m353m355m353m345m338m335m329m326m325m318m312m307m300m296m291m285m283m
Shares outstanding at period endn/an/an/an/a591m595m602m608m611m614m322m318m309m306m302m295m292m285m283m282m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008 †FY2009 †FY2010FY2011FY2012 †FY2013 †FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity3,2342,5592,5063,2284,3085,1825,2865,2984,1674,2434,8314,5674,7484,8735,3895,3055,8455,8986,7417,363
Non-controlling interest14.014.08.08.08.03.03.03.03.03.04.04.00.0n/an/an/an/an/an/an/a
Short-term borrowingsn/an/a1.0n/an/an/a0.0n/an/an/an/a0.0n/an/a0.0n/a0.0n/an/an/a
Debtn/a1,5142,9043,6912,1852,3622,6991,6631,6551,9042,0111,7922,4072,3592,7292,7692,7353,3903,3543,949
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/an/a127130101118142145n/a
Other liabilitiesn/a2,9202,1932,7692,5562,9892,6983,8671,6541,6521,5802,1782,2972,2682,4572,3572,0652,4162,4872,655
Total liabilities and equityn/a7,0077,6129,6969,05710,53610,68610,8317,4797,8028,4268,5419,4529,62710,70510,53210,76311,84612,72713,967
Owned
Fixed assetsn/a8248459801,0061,1641,1346316046397578228508459451,1001,2701,7782,0232,134
Goodwilln/a6466551,4561,5673,0252,6282,5072,3662,5172,6072,9733,5933,6023,9753,9523,9604,4774,4735,030
Intangible assetsn/a2281674944291,0869166494454163614911,107831981821475547445906
Investmentsn/a23017714211712013996.086.013513868.0102158185195164175133130
Trading assetsn/an/an/an/an/an/an/an/an/an/an/a30.030.030.034.031.036.043.041.0n/a
Cash and equivalents1,8261,4052,4792,6493,5272,3512,6752,2182,0032,2892,6782,2471,3821,4411,4841,0531,5901,3291,7891,758
Receivablesn/a7705958698609238996266066317247769301,0381,1721,4051,2911,3241,4871,478
Inventoryn/a6465527168981,0141,0665745415335756386797208301,0381,0319721,0251,117
Other assetsn/a2,2582,1422,3906538531,2293,5308286425864967799621,0999379461,2011,3111,414
Total assetsn/a7,0077,6129,6969,05710,53610,68610,8317,4797,8028,4268,5419,4529,62710,70510,53210,76311,84612,72713,967
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded5.6%5.4%0.5%8.6%
Profit growth, compounded12.5%12.6%1.3%18.0%
Return on equity, average17.8%21.7%20.8%19.3%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

When does Agilent Technologies report its next earnings?

Agilent Technologies has announced its next results for 23 Nov 2026.

What was Agilent Technologies' revenue in fiscal 2025?

Agilent Technologies (A) reported revenue of $6.9 billion for fiscal 2025, the year ended 31 October 2025, up 6.7% on the year before.

How much did Agilent Technologies earn in fiscal 2025?

Net income was $1.3 billion for fiscal 2025, and diluted earnings per share $4.57.

What is Agilent Technologies' P/E ratio?

At the close of 6 November 2026, Agilent Technologies traded at 34.4 times its earnings over the twelve months to 31 July 2026.

What is Agilent Technologies' market cap?

The market cap of Agilent Technologies was $49.3 billion at the close of 6 November 2026.

Does Agilent Technologies pay a dividend?

Yes. Agilent Technologies declared $1.01 a share in dividends over the four quarters to 31 July 2026.

Peers: Measuring and Control Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Agilent Technologies, Inc. A$49.3 billion34.4019.6%22.2%8.6%0.540.6%
Waters Corp. WAT$45.0 billion114.141.1%7.1%52.5%0.33n/a
Mettler Toledo International Inc. MTD$37.3 billion37.301,202.8%n/a6.5%26.06n/a
Illumina, Inc. ILMN$32.2 billion36.6728.5%21.2%5.8%0.57n/a
Revvity, Inc. RVTY$17.3 billion73.893.3%12.3%4.1%0.450.2%
Avantor, Inc. AVTR$10.5 billion30.935.8%7.3%0.9%0.63n/a
Bio-Rad Laboratories, Inc. BIO$10.3 billion10.0613.5%-2.4%1.4%0.16n/a
Bruker Corp. BRKR$9.4 billionn/a-5.4%-2.0%2.2%0.74n/a
10x Genomics, Inc. TXG$7.8 billionn/a-8.0%-11.7%-3.6%0.00n/a
Alamar Biosciences, Inc. ALMR$1.9 billionn/a-18.1%-42.1%n/a0.00n/a
Cytek Biosciences, Inc. CTKB$765 millionn/a-25.3%-21.1%5.5%0.00n/a
Pacific Biosciences of California, Inc. PACB$703 millionn/an/a-81.3%4.4%n/a0.0%
All 49 in Measuring and Control Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Thermo Fisher Scientific Inc. TMO$257.5 billion36.6512.9%17.9%8.3%0.760.3%
KLA Corp. KLAC$180.5 billion34.6280.6%n/a15.8%0.880.6%
Danaher Corp. DHR$162.0 billion37.698.1%20.4%5.5%0.490.6%
Trane Technologies plc TT$88.0 billion28.3834.6%17.9%10.3%0.461.0%
AMETEK Inc. AME$52.4 billion32.2513.9%26.0%14.3%0.570.6%
Agilent Technologies, Inc. A$49.3 billion34.4019.6%22.2%8.6%0.540.6%
Roper Technologies Inc. ROP$47.2 billion18.8113.5%28.0%9.2%0.510.8%
Keysight Technologies, Inc. KEYS$46.3 billion37.3319.2%20.3%25.5%0.38n/a
Waters Corp. WAT$45.0 billion114.141.1%7.1%52.5%0.33n/a
Rockwell Automation, Inc. ROK$41.7 billion35.2134.4%22.7%11.3%0.931.5%
Coherent Corp. COHR$38.0 billion40.018.5%12.5%30.8%0.35n/a
Mettler Toledo International Inc. MTD$37.3 billion37.301,202.8%n/a6.5%26.06n/a
Teradyne, Inc. TER$34.1 billion25.0537.2%32.1%74.9%0.000.2%
Illumina, Inc. ILMN$32.2 billion36.6728.5%21.2%5.8%0.57n/a
Veralto Corp. VLTO$28.5 billion28.9831.0%21.8%6.4%0.900.4%
Fortive Corp. FTV$19.5 billion31.1411.0%19.6%7.0%0.590.4%
Revvity, Inc. RVTY$17.3 billion73.893.3%12.3%4.1%0.450.2%
MKS Inc. MKSI$13.0 billion22.8018.3%18.2%24.6%1.150.5%
Trimble Inc. TRMB$12.4 billionn/a-3.2%16.5%6.9%0.31n/a
Avantor, Inc. AVTR$10.5 billion30.935.8%7.3%0.9%0.63n/a
Bio-Rad Laboratories, Inc. BIO$10.3 billion10.0613.5%-2.4%1.4%0.16n/a
Bruker Corp. BRKR$9.4 billionn/a-5.4%-2.0%2.2%0.74n/a
Onto Innovation Inc. ONTO$8.5 billion65.106.9%12.0%8.1%0.00n/a
Cognex Corp. CGNX$8.0 billion33.3714.1%25.0%15.8%0.000.7%
10x Genomics, Inc. TXG$7.8 billionn/a-8.0%-11.7%-3.6%0.00n/a
Ralliant Corp. RAL$7.5 billionn/a-73.4%-48.3%n/a0.710.3%
Sensata Technologies Holding plc ST$5.7 billion15.7212.0%15.1%4.1%0.781.2%
Vontier Corp. VNT$5.7 billion17.3028.4%19.4%0.3%1.570.2%
Badger Meter Inc. BMI$4.5 billion36.4719.4%18.8%-2.2%0.001.0%
Mirion Technologies, Inc. MIR$4.4 billion149.581.6%6.0%19.6%0.67n/a
Itron, Inc. ITRI$4.3 billion15.9016.5%13.7%-3.6%0.95n/a
Alamar Biosciences, Inc. ALMR$1.9 billionn/a-18.1%-42.1%n/a0.00n/a
Cohu Inc. COHU$1.9 billionn/a-2.9%-2.4%34.0%0.38n/a
Aehr Test Systems AEHR$1.7 billion1,338.881.0%-5.6%26.8%0.00n/a
Allient Inc. ALNT$1.4 billion36.6811.4%9.8%12.6%0.530.2%
Transcat Inc. TRNS$953 millionn/an/an/an/a0.38n/a
Cytek Biosciences, Inc. CTKB$765 millionn/a-25.3%-21.1%5.5%0.00n/a
Mesa Laboratories Inc. MLAB$718 million152.762.5%9.0%3.0%0.760.5%
Pacific Biosciences of California, Inc. PACB$703 millionn/an/a-81.3%4.4%n/a0.0%
Frequency Electronics Inc. FEIM$661 million241.042.2%2.5%6.3%0.00n/a
Senseonics Holdings, Inc. SENS$454 millionn/a-121.1%-223.2%90.6%0.62n/a
908 Devices Inc. MASS$402 millionn/an/an/an/a0.00n/a
Quantum-Si Inc. QSI$291 millionn/a-53.1%-7,474.5%-60.2%0.00n/a
Nautilus Biotechnology, Inc. NAUT$284 millionn/an/an/an/a0.00n/a
Intest Corp. INTT$173 million38.593.4%3.3%16.6%0.05n/a
Hurco Companies Inc. HURC$132 millionn/a-3.4%-2.8%-1.9%n/an/a
Kewaunee Scientific Corp. KEQU$97 million12.1411.0%5.4%5.3%0.25n/a
Seer, Inc. SEER$90 millionn/a-30.1%-498.2%-12.7%0.000.0%
Rapid Micro Biosystems, Inc. RPID$32 millionn/a-288.5%-141.5%16.1%1.08n/a
15 companies share its SEC industry code (Laboratory Analytical Instruments); the rest are the names nearest in size in its wider industry, Measuring and Control Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on A

Dividends$1.013 a share over the four quarters to 31 July 2026, a 0.58% yield
Filings22 in twelve months: 11 current reports (8-K), about 5 officer or director change; 4 results of operations; 2 regulation FD disclosure; 1 material agreement; 1 new financial obligation
Planned insider sales6 Form 144 notices in twelve months, $3.2 million; latest 4 September 2026
Options tapeput/call 0.69 by open interest at the 6 November 2026 close; the straddle prices a 6.4% move to 20 November 2026
13F holders1,141 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading6 sales and 0 purchases on Form 4 in twelve months
Congress2 House trades disclosed in six months
Short interest5.0 million shares short, 2.42 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q31 July 20261 September 2026EDGAR
10-Q30 April 20261 June 2026EDGAR
10-Q31 January 20263 March 2026EDGAR
10-K31 October 202522 December 2025EDGAR
10-Q31 July 202529 August 2025EDGAR
10-Q30 April 20252 June 2025EDGAR
10-Q31 January 20253 March 2025EDGAR
10-K31 October 202420 December 2024EDGAR
10-Q31 July 202430 August 2024EDGAR
10-Q30 April 20243 June 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.